Publikationen von Michael Werner Sereda

Hartmannsberger, B.; Doppler, K.; Stauber, J.; Schlotter-Weigel, B.; Young, P.; Sereda, M. W.: Intraepidermal nerve fibre density as biomarker in Charcot–Marie–Tooth disease type 1A. Brain Communications (2020)

Joseph, S.; Vingill, S.; Jahn, O.; Fledrich, R.; Werner, H. B.; Katona, I.; Möbius, W.; Mitkovski, M.; Huang, Y.; Weis, J. et al.; Sereda, M. W.; Schulz, J. B.; Nave, K.-A.; Stegmüller, J.: Myelinating glia-specific deletion of Fbxo7 in mice triggers axonal degeneration in the central nervous system together with peripheral neuropathy. The Journal of Neuroscience 39 (28), S. 5606 - 5626 (2019)

Fledrich, R.; Akkermann, D.; Schütza, V.; Abdelaal, T. A. M.; Hermes, D.; Schäffner, E.; Soto Bernardini, M. C.; Götze, T.; Klink, A.; Kusch, K. et al.; Krueger, M.; Kungl, T.; Frydrychowicz, C.; Möbius, W.; Brück, W.; Mueller, W. C.; Bechmann, I.; Sereda, M. W.; Schwab, M. H.; Nave, K.-A.; Stassart, R. M.: NRG1 type I dependent autoparacrine stimulation of Schwann cells in onion bulbs of peripheral neuropathies. Nature Communications 10 (1), 1840 (2019)

Prukop, T.; Stenzel, J.; Wernick, S.; Kungl, T.; Mroczek, M.; Adam, J.; Ewers, D.; Nabirotchkin, S.; Nave, K.-A.; Hajj, R. et al.; Cohen, D.; Sereda, M. W.: Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A). PLoS One 14 (1), e0209752 (2019)

Fledrich, R.; Abdelaal, T. A. M.; Rasch, L.; Bansal, V.; Schütza, V.; Brügger, B.; Lüchtenborg, C.; Prukop, T.; Stenzel, J.; Rahman, R.U. et al.; Hermes, D.; Ewers, D.; Möbius, W.; Ruhwedel, T.; Katona, I.; Weis, J.; Klein, D.; Martini, R.; Brück, W.; Müller, W.C.; Bonn, S.; Bechmann, I.; Nave, K.-A.; Stassart, R. M.; Sereda, M. W.: Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy. Nature Communications 9 (1), 3025 (2018)

Fledrich, R.; Mannil, M.; Leha, A.; Ehbrecht, C.; Solari, A.; Pelayo-Negro, A. L.; Berciano, J.; Schlotter-Weigel, B.; Schnizer, T. J.; Prukop, T. et al.; Garcia-Angarita, N.; Czesnik, D.; Haberlová, J.; Mazanec, R.; Paulus, W.; Beissbarth, T.; Walter, M. C.; CMT-TRIAAL; Hogrel, J.-Y.; Dubourg, O.; Schenone, A.; Baets, J.; De Jonghe, P.; Shy, M. E.; Horvath, R.; Pareyson, D.; Seeman, P.; Young, P.; Sereda, M. W.: Biomarkers predict outcome in Charcot-Marie-Tooth disease 1A. Journal of Neurology, Neurosurgery & Psychiatry 88 (11), S. 941 - 952 (2017)

Kleinecke, S.; Richert, S.; de Hoz, L.; Brügger, B.; Kungl, T.; Asadollahi, E.; Quintes, S.; Blanz, J.; McGonigal, R.; Naseri, K. et al.; Sereda, M. W.; Sachsenheimer, T.; Lüchtenborg, C.; Möbius, W.; Willison, H.; Baes, M.; Nave, K.-A.; Kassmann, C. M.: Peroxisomal dysfunctions cause lysosomal storage and axonal Kv1 channel redistribution in peripheral neuropathy. eLife 6, e23332 (2017)

Günther, R.; Balck, A.; Koch, J. C.; Nientiedt, T.; Sereda, M.; Bähr, M.; Lingor, P.; Tönges, L.: Rho kinase inhibition with Fasudil in SOD1(G93A) mouse model of Amyotrophic Lateral Sclerosis - symptomatic treatment potential after diesease onset. Frontiers in Pharmacology 8, 17 (2017)

Quintes, S.; Brinkmann, B. G.; Ebert, M.; Fröb, F.; Kungl, T.; Arlt, F. A.; Tarabykin, V.; Huylebroeck, D.; Meijer, D.; Suter, U. et al.; Wegner, M.; Sereda, M. W.; Nave, K.-A.: Zeb2 is essential for Schwann cell differentiation, myelination and nerve repair. Nature Neuroscience, 10.1038/nn.4321 (2016)

Sociali, G.; Visigalli, D.; Prukop, T.; Cervellini, I.; Mannino, E.; Venturi, C.; Bruzzone, S.; Sereda, M. W.; Schenone, A.: Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy. Neurobiology of Disease 95 (11), S. 145 - 157 (2016)

Pehlivan, D.; Beck, C. R.; Okamoto, Y.; Harel, T.; Akdemir, Z. H. C.; Jhangiani, S. N.; Withers, M. A.; Goksungur, M. T.; Carvalho, C. M. B.; Czesnik, D. et al.; Wiszniewski, W.; Muzny, D. M.; Gibbs, R. A.; Rautenstrauss, B.; Sereda, M. W.; Lupski, J. R.: The role of combined SNV and CNV burden in patients with distal symmetric polyneuropathy. Genetics in Medicine 18 (5), S. 443 - 451 (2015)

Ekins, S.; Litterman, N. K.; Arnold, R. J. G.; Burgess, R. W.; Freundlich, J. S.; Gray, S. J.; Higgins, J. J.; Langley, B.; Willis, D. E.; Notterpek, L. et al.; Pleasure, D.; Sereda, M. W.; Moore, A.: A brief review of recent Charcot-Marie-Tooth research and priorities. Faculty of 1000 Research 4, 53 (2015)

Epplen, D. B.; Prukop, T.; Nientiedt, T.; Albrecht, P.; Arlt, F. A.; Stassart, R. M.; Kassmann, C. M.; Methner, A.; Nave, K.-A.; Werner, H. B. et al.; Sereda, M. W.: Curcumin therapy in a Plp1 transgenic mouse model of Pelizaeus-Merzbacher disease. Annals of clinical and translational neurology 2 (8), S. 787 - 796 (2015)

Patzig, J.; Kusch, K.; Fledrich, R.; Eichel, M. A.; Lüders, K. A.; Möbius, W.; Sereda, M. W.; Nave, K.-A.; Martini, R.; Werner, H. B.: Proteolipid protein modulates preservation of peripheral axons and premature death when myelin protein zero is lacking. Glia 64 (1), S. 155 - 174 (2015)

Chumakov, I.; Milet, A.; Cholet, N.; Primas, G.; Boucard, A.; Pereira, Y.; Graudens, E.; Mandel, J.; Laffaire, J.; Foucquier, J. et al.; Glibert, F.; Bertrand, V.; Nave, K.-A.; Sereda, M. W.; Vial, E.; Guedj, M.; Hajj, R.; Nabirotchkin, S.; Cohen, D.: Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy. Orphanet Journal of Rare Diseases 9 (1), 201 (2014)

Avenali, L.; Narayanan, P.; Rouwette, T.; Cervellini, I.; Sereda, M.; Gomez-Varela, D.; Schmidt, M.: Annexin A2 regulates TRPA1-dependent nociception. Journal of Neuroscience 34 (44), S. 14506 - 14516 (2014)

Fledrich, R.; Stassart, R. M.; Klink, A.; Rasch, L. M.; Prukop, T.; Haag, L.; Czesnik, D.; Kungl, T.; Abdelaal, T. A. M.; Keric, N. et al.; Stadelmann, C.; Brück, W.; Nave, K.-A.; Sereda, M. W.: Soluble neuregulin-1 modulates disease pathogenesis in rodent models of Charcot-Marie-Tooth disease 1A. Nature Medicine 20 (9), S. 1055 - 1061 (2014)

Prukop, T.; Epplen, D. B.; Nientiedt, T.; Wichert, S. P.; Fledrich, R.; Stassart, R. M.; Rossner, M. J.; Edgar, J. M.; Werner, H. B.; Nave, K.-A. et al.; Sereda, M. W.: Progesterone antagonist therapy in a Pelizaeus-Merzbacher mouse model. American Journal of Human Genetics 94, S. 533 - 546 (2014)

Tönges, L.; Günther, R.; Suhr, M.; Jansen, J.; Balck, A.; Saal, K.-A.; Barski, E.; Nientied, T.; Götz, A. A.; Koch, J.-C. et al.; Mueller, B. K.; Weishaupt, J. H.; Sereda, M. W.; Hanisch, U.-K.; Bähr, M.; Lingor, P.: Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis. GLIA 62 (2), S. 217 - 232 (2014)

Mannil, M.; Solari, A.; Leha, A.; Pelayo-Negro, A. L.; Berciano, J.; Schlotter-Weigel, B.; Walter, M. C.; Rautenstrauss, B.; Schnizer, T. J.; Schenone, A. et al.; Seeman, P.; Kadian, C.; Schreiber, O.; Angarita, N. G.; Fabrizi, G. M.; Gemignani, F.; Padua, L.; Santoro, L.; Quattrone, A.; Vita, G.; Calabrese, D.; CMT-TRIAAL/CMT-TRAUK Group; Young, P.; Laurà, M.; Haberlová, J.; Mazanec, R.; Paulus, W.; Beissbarth, T.; Shy, M. E.; Reilly, M. M.; Pareyson, D.; Sereda, M. W.: Selected items from the Charcot-Marie-Tooth (CMT) neuropathy score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients. Neuromuscular Disorders 24, S. 1003 - 1017 (2014)